KLF5 is a transcription factor that binds GC box promoter elements to activate RNA polymerase II-dependent transcription. Beyond its canonical role in gene regulation, KLF5 functions as a key node in disease-specific transcriptional circuitries. In esophageal squamous cell carcinoma, KLF5 is part of a core regulatory circuit with TP63 and SOX2 that controls chr13 accessibility and super-enhancer activity; inhibition of histone deacetylases disrupted this program and slowed xenograft tumor growth 1. KLF5 regulates disease progression through diverse mechanisms: it promotes epithelial-mesenchymal transition in diabetic kidney disease via histone lactylation-dependent upregulation and subsequent repression of CDH1 2, drives oxidative stress in diabetic cardiomyopathy by inducing NOX4 expression 3, and enhances actin remodeling and metastasis in nasopharyngeal carcinoma through ACTN4 transcription 4. In ovarian cancer, KLF5 transcriptionally activates RAD51, strengthening homologous recombination repair and conferring PARP inhibitor resistance; combined histone deacetylase and PARP inhibition overcame this resistance 5. KLF5 also suppresses anti-tumor immunity by promoting COX2-mediated prostaglandin E2 release; KLF5 inhibition combined with anti-PD1 therapy enhanced CD8+ T cell infiltration and efficacy 6. In prostate cancer contexts, KLF5 acetylation status regulates fibroblast-mediated tumor progression, and KLF5 controls castration-resistant phenotypes responsive to retinoic acid receptor agonists 78. These findings nominate KLF5 as a targetable node in multiple malignancies and fibrotic diseases.